The gelatin-based solution not only helps optimize the production process of nutraceutical gummies, but also enables producers to bring tasty, innovative and competitive delivery forms to the market.
“We’re delighted to have achieved this important step in protecting our innovative SiMoGel solution,” says Marit van der Heijden, Global Marketing & Project Manager at Rousselot. “The patent grant by the EPO strengthens our current patent portfolio and confirms that we are delivering truly innovative solutions to the market. In securing this patent, we are able to offer our customers even more opportunities for secure product development, allowing them to tap into the growing nutraceutical gummy market.”
Over the past few years, nutraceutical gummies have proven to be a popular delivery form achieving a CAGR of 37.3% from 2016 to 2020(1). As the market continues to expand, so too do the opportunities. To further improve gummies as a delivery form, Rousselot recently launched a new SiMoGel-based process solution, which enables the production of center-filled nutraceutical gummies – also known as gummy caps. This unique concept combines the benefits of soft gels and gummies in a single delivery form – making it the first of its kind to be launched on the nutraceutical and pharmaceutical markets.
Van der Heijden concludes, “We are committed to using gelatin as the preferred excipient in this application, as we believe its many functional benefits and natural origins bring endless possibilities for consumers to enjoy their daily vitamins, and even medicines. Rousselot’s team is looking forward to applying the SiMoGel concept in collaboration with our customers to create innovative products, such as 3D gummies, coming with visually appealing and palatable shapes. Our teams of food and nutrition experts are particularly eager to provide formulation support and help nutra- and pharmaceutical players reach their new product development goals.”
The patent granted by the EPO (ref. EP3570680B1) is effective in all major countries in Europe and is pending in Brazil, Japan and the United States.
[1] Innova Market Insights